This review paper was presented at the European Association of Urology (EAU) Section of Oncological Urology (ESOU) conference in Prague, Czech Republic last week.
Results from the CARMENA study were reviewed and recommendations made for cytoreductive nephrectomy for people with advanced renal cell carcinoma (RCC). CARMENA is a randomised clinical trial comparing patients who had either cytoreductive nephrectomy and sunitinib versus sunitinib alone without cytoreductive nephrectomy. Patients were recruited primarily from France, but also the UK.
Conclusions took into account the results from both the SURTIME study and the CARMENA trial. SURTIME compared immediate verses delayed cytoreductive nephrectomy in patients who were taking sunitinib.